Given that the Delta and Omicron variants can elicit enhanced calprotectin production by Dok3-/- neutrophils through a TLR4-dependent manner, it is likely that therapeutic strategies which suppress calprotectin production by neutrophils may still be effective in preventing severe COVID-19 manifestations in patients infected with these variants. This evidence concerns the gene DOK3 and COVID-19.